Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Microvascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d, An orphan category in Banff classification with cytotoxic T and natural killer cell infiltration

  • Buxeda, Anna|||0000-0001-7305-3259
  • Llinàs Mallol, Laura|||0000-0003-4696-3331
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Arias Cabrales, Carlos E.|||0000-0002-1729-8152
  • Burballa, Carla|||0000-0002-0091-1459
  • Puche, Adrian
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Yélamos, José|||0000-0003-1195-1496
  • Vilches, Carlos|||0000-0002-0300-9225
  • Naesens, Maarten|||0000-0002-5625-0792
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Pascual, Julio|||0000-0002-4735-7838
  • Crespo, Marta|||0000-0001-6992-6379
Isolated microvascular inflammation (iMVI) without HLA donor-specific antibodies or C4d deposition in peritubular capillaries remains an enigmatic phenotype that cannot be categorized as antibody-mediated rejection (ABMR) in recent Banff classifications. We included 221 kidney transplant recipients with biopsies with ABMR (n = 73), iMVI (n = 32), and normal (n = 116) diagnoses. We compared peripheral blood leukocyte distribution by flow cytometry and inflammatory infiltrates in kidney transplant biopsies among groups. Flow cytometry showed fewer lymphocytes and total, CD4, and CD8 peripheral T cells in iMVI compared with ABMR and normal cases. ABMR and iMVI had fewer total natural Killer (NK) cells but more NKG2A NK cells. Immunohistochemistry indicated that ABMR and iMVI had greater CD3 and CD68 glomerular infiltration than normal biopsies, whereas CD8 and TIA1 cells showed only increased iMVI, suggesting they are cytotoxic T cells. Peritubular capillaries displayed more CD3, CD56, TIA1, and CD68 cells in both ABMR and iMVI. In contrast, iMVI had less plasma cell infiltration in peritubular capillaries and interstitial aggregates than ABMR. iMVI displayed decreased circulating T and NK cells mirrored by T cell and NK cell infiltration in the renal allograft, similar to ABMR. However, the lesser plasma cell infiltration in iMVI may suggest an antibody-independent underlying stimulus.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and molecular spectrum of v-lesion

  • Buxeda, Anna|||0000-0001-7305-3259
  • Crespo, Marta|||0000-0001-6992-6379
  • Chamoun, Betty|||0000-0002-4267-2273
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Torres, Irina B.|||0000-0003-3304-0810
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Burballa, Carla|||0000-0002-0091-1459
  • Pascual, Julio|||0000-0002-4735-7838
  • Mengel, Michael|||0000-0002-7222-3356
  • Adam, Benjamin|||0000-0003-1908-1739
  • Pérez-Sáez, María José|||0000-0002-8601-2699
Isolated v-lesion presents diagnostic stratification and clinical challenges. We characterized allograft outcomes for this entity based on posttransplant time (early: ≤1 month vs late:.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased mortality after kidney transplantation in mildly frail recipients

  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Arias Cabrales, Carlos E|||0000-0002-1729-8152
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Burballa, Carla|||0000-0002-0091-1459
  • Buxeda, Anna|||0000-0001-7305-3259
  • Bach Pascual, Anna|||0000-0003-0571-6131
  • Faura, Anna|||0000-0002-1440-3922
  • Junyent, Ernestina
  • Marco, Ester|||0000-0002-3412-0356
  • Rodríguez-Mañas, Leocadio|||0000-0002-6551-1333
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
Physical Frailty Phenotype (PFP) is the most used frailty instrument among kidney transplant recipients, classifying patients as pre-frail if they have 1-2 criteria and as frail if they have ≥3. However, different definitions of robustness have been used among renal patients, including only those who have 0 criteria, or those with 0-1 criteria. Our aim was to determine the impact of one PFP criterion on transplant outcomes. We undertook a retrospective study of 296 kidney transplant recipients who had been evaluated for frailty by PFP at the time of evaluating for transplantation. Only 30.4% of patients had 0 criteria, and an additional 42.9% showed one PFP criterion. As PFP score increased, a higher percentage of women and cerebrovascular disease were found. Recipients with 0-1 criteria had lower 1-year mortality after transplant than those with ≥2 (1.8% vs 10.1%), but this difference was already present when we only considered those who scored 0 (mortality 1.1%) and 1 (mortality 2.4%) separately. The multivariable analysis confirmed that one PFP criterion was associated to a higher risk of patient death after kidney transplantation [hazard ratio 3.52 (95% confidence interval 1.03-15.9)]. Listed kidney transplant candidates frequently show only one PFP frailty criterion. This has an independent impact on patient survival after transplantation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

  • Buxeda, Anna|||0000-0001-7305-3259
  • Arias Cabrales, Carlos E.|||0000-0002-1729-8152
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Cacho, Judit
  • Cabello Pelegrín, Sheila|||0000-0001-9319-6935
  • Melilli, Edoardo|||0000-0001-6965-3745
  • Aladrén Regidor, Mª José|||0000-0002-1043-9979
  • Galeano Alvarez, Cristina|||0000-0003-2785-8886
  • Lorenzo, Iinmaculada
  • Mazuecos, Auxiliadora|||0000-0002-5860-2309
  • Saura, Isabel María
  • Franco, Antonio
  • Ruiz-Fuentes, María del Carmen
  • Sánchez-Cámara, Luis Alberto
  • Siverio, Orlando
  • Martin, María Luisa
  • González-García, Elena
  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Martin-Moreno, Paloma Leticia
  • Moina, Iñigo
  • Moral Berrio, Esperanza
  • Moreso, Francesc|||0000-0002-7267-3963
  • Portolés, José María
  • Santana-Estupiñán, Raquel
  • Zárraga, Sofía
  • Canal Girol, Cristina|||0000-0003-2556-872X
  • Sánchez-Álvarez, Emilio
  • Pascual, Julio|||0000-0002-4735-7838
  • Crespo, Marta|||0000-0001-6992-6379
Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.